http://www.acc.org/Feed?clinicalTopicID=af87f19c-b38d-4ead-99f0-12dbb1291f20 Clinical Topic Feed: Aortic Surgery en /Latest-in-Cardiology/Articles/2026/04/01/01/Mission-in-Action-Medtronic-Clinician-Update New long-term data from the Evolut Low Risk trial published in JACC underscore how emerging science and evidence continue to shape patient-centered care in structural heart disease – an approach central to the ACC's Vision of using science, knowledge and innovation to optimize patient care and outcomes. 1775045220000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/25/21/27/sun-4pm-protavi-acc-2026 Older patients with coronary artery disease (CAD) for whom PCI was deferred until after TAVI had similar outcomes as those for whom it was not deferred, according to findings from the PRO-TAVI study presented in a Late-Breaking Clinical Trial session... 1774818600000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/25/21/27/sun-4pm-protecth2h-acc-2026 In the first head-to-head comparison of two embolic protection devices used during TAVR, the investigational Emboliner protection catheter performed comparably to the U.S. Food and Drug Administration (FDA)-approved Sentinel cerebral protection system relative to the composite primary endpoint and secondary endpoint of stroke, according to results from the PROTECT H2H trial presented during a Late-Breaking Clinical Trial session at ACC.26 in New Orleans. 1774818180000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/18/11/31/Trilogy-TAVI-For-Native-Aortic-Regurgitation The ALIGN-AR (TAVR With JenaValve for Symptomatic Aortic Regurgitation in High Surgical Risk Patients) trial findings demonstrated that, among patients with symptomatic moderate-to-severe or severe native aortic regurgitation (AR) at high surgical risk, transcatheter aortic valve implantation (TAVI) using the Trilogy valve... 1773930000000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/03/17/16/54/CathPCI-Registry-Findings Recent studies informed by data from ACC's CathPCI Registry explore trends in PCI for stent thrombosis; contrast media dosing during PCI; acute kidney injury (AKI) and same-day discharge (SDD); and disparities in use of atherectomy and intravascular lithotripsy (IVL) during PCI. 1773769020000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/03/12/18/50/dancavas Severe aortic and iliac calcification was associated with a significantly higher risk of major adverse limb events (MALEs) and aortic events, according to a prospective cohort study from the DANCAVAS trials published March 2 in Circulation. These results suggest that quantifying aortic calcification may provide valuable prognostic information and improve the risk stratification in patients with peripheral artery disease or aortic aneurysm. 1773343260000 Articles and Stories /Latest-in-Cardiology/Articles/2026/02/26/17/54/Medtronic-Clinician-Update-on-New-Evolut-Valve-Data-Reinforces-Need-For-Patient-Dialogue Medtronic has issued a letter and developed web resources providing an update on long-term reintervention rates associated with its Evolut R and Evolut PRO transcatheter heart valves, drawing on complete six-year and partial seven-year follow-up data from the Evolut Low-Risk Trial published on Feb. 16 in JACC. 1772128800000 Articles and Stories /Latest-in-Cardiology/Articles/2026/02/24/16/30/eagles-eye-view-24feb2025 In this week’s View, Dr. Eagle looks at findings from the Evolut Low Risk trial in which self-expanding transcatheter aortic valve replacement (TAVR) versus surgery at six years in low-risk patients with aortic stenosis (AS) is considered. 1772031600000 Articles and Stories /Latest-in-Cardiology/Articles/2026/02/19/11/58/Hot-Topics-in-Congenital-and-Pediatric-Cardiology-in-the-Year-2025 The pace of innovation in congenital and pediatric cardiology continued to accelerate in 2025, shaped by practice‑defining guidelines, multicenter investigations, and growing bench‑to‑bedside translation. 1771850460000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/02/13/21/24/EVOLUT-LOW-RISK-Self-Expanding-TAVR-vs-Surgery-at-Six-Years Six years after undergoing either surgery or TAVR with a CoreValve, Evolut R or Evolut PRO, low-risk patients with aortic stenosis (AS) experienced no significant differences in terms of all-cause mortality or disabling stroke, according to findings from the Evolut Low Risk trial published in JACC. However, researchers observed higher reintervention rates among those assigned to TAVR compared with surgery, largely due to increased incidence of aortic regurgitation (AR). 1771254000000 Articles and Stories